Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Compiles Optimal Promotion Guidelines for Kymriah
May 16, 2019
- Coefficients for Cost-Based Pricing Formula Updated: Chuikyo
May 16, 2019
- As Kymriah Fetches Highest List Price, Policymakers Talk over Difficulty in Cell Therapy Pricing
May 16, 2019
- Alnylam’s siRNA Drug Patisiran Up for MHLW Panel Review on May 28
May 16, 2019
- Japan OKs Listing of Trelegy, Erleada, and More; GSK’s COPD Hopeful to Face Cost-Effectiveness Analysis
May 15, 2019
- Opdivo to Face CEA-Based Price Tweaks on Aug. 1
May 15, 2019
- Kymriah Gets 33.5 Million Yen Price Tag, Peak Sales Put at 7.2 Billion Yen
May 15, 2019
- 87% of Drug Makers Say 2018 Pricing Reform Hit Their R&D, Businesses: MHLW Survey
May 15, 2019
- Newly Sworn In Chief Gives “4 First” Pep Talk to PMDA Staffers
May 14, 2019
- Kymriah Likely to Fetch 33 Million Yen Price Tag, Collategene to Skip Listing
May 14, 2019
- Xofluza, Opdivo, Keytruda, Bavencio under PMDA Risk Review
May 13, 2019
- Pituitary Dysfunction Added to Significant Adverse Reaction for Opdivo: MHLW
May 10, 2019
- MHLW Launches Survey on Authorized Generics to Get Data for Chuikyo Debate
May 8, 2019
- Next Public-Private Confab Set for May 20 before Full-Swing Pricing Debate
May 8, 2019
- Entyvio’s Crohn’s Disease Indication in Line for Approval in May
May 7, 2019
- Chuikyo Agrees to Require Genetic Info Submission for Insurance Coverage of Cancer Genomic Panel Tests
April 25, 2019
- PMDA to Set Up New Consultation Services for RWD Use in Regulatory Submissions
April 24, 2019
- MOF Pitches Higher Copay for Pricey Drugs Deemed Not Cost Effective
April 23, 2019
- Lilly’s EGFR Antagonist, Japan’s 1st Avastin Biosimilar Now in Line for June Approval
April 22, 2019
- CEA Use in Reimbursement Decisions Our Ultimate Goal: MOF Budget Examiner
April 19, 2019
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…